Skip to main content
Delfa

← All assets

Subcutaneous · GLP-1 agonist

MET097 / PF-08653944

12 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.

Trials

12

Ongoing

9

Recruiting

7

Completed

3

Sites

330

Countries

11

Endpoints

203

Composite endpoints

0

Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.

Where the program stands

Trials by phase

Phase 1
3
Phase 1/2
2
Phase 2
4
Phase 3
3

Trials by status

Recruiting
7
Active, not recruiting
2
Completed
3

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Weight & body composition
75
Safety / tolerability / PK
52
Cardiometabolic biomarkers
30
Glycemic / diabetes
21
Other (unclassified)
13
Patient-reported / QoL
12

Top 20 metrics across this asset's endpoints

Programs for this asset

Every trial for this molecule, with the same search, filters, and sort as the Trials tab.

12 of 12

GLP-1 and incretin trials
Asset / PopulationEligibility highlightEvidence
VESPER-4Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

MET097 / PF-08653944

Obesity / overweight

BMI 27-30Ph 3Recruiting218Sep 2027-
NCT07400653A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

MET097 / PF-08653944

Obesity / overweight, Type 2 diabetes

BMI ≥27Ph 3Recruiting188Oct 2027-
SOLIS-1A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

MET097 / PF-08653944

Obesity / overweight

BMI 30-50Ph 2Recruiting48Aug 2027-
VESPER-2A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

MET097 / PF-08653944

Obesity / overweight, Type 2 diabetes

BMI 27-50Ph 2Completed29Dec 2025-
NCT07595549A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

MET097 / PF-08653944

Obesity / overweight

BMI 27-30Ph 3Recruiting10May 2028-
VESPER-3A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

MET097 / PF-08653944

Obesity / overweight

-Ph 2Active, not recruiting5Dec 2025-
NCT06857617This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity

MET097 / PF-08653944

Obesity / overweight

BMI 27-38Ph 1/2Completed3Jan 2025-
NCT07519135A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function

MET097 / PF-08653944

Healthy volunteers, Hepatic impairment

BMI ≥21Ph 1Recruiting3Jul 2027-
VESPER-1A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight

MET097 / PF-08653944

Obesity / overweight

-Ph 2Completed2Jul 2025-
NCT07508241A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

MET097 / PF-08653944

Healthy volunteers, Obesity / overweight

BMI 27-45Ph 1Recruiting1Jan 2027-
NCT06924320A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

MET097 / PF-08653944, MET233

Obesity / overweight, Type 2 diabetes

BMI 27-38Ph 1/2Recruiting1Sep 2026-
NCT07400679A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity

MET097 / PF-08653944

Obesity / overweight

BMI 27-45Ph 1Active, not recruiting1Sep 2026-

Showing 1-12 of 12 trials